Compare stocks

GNLX vs KNSA

Genelux Corporation Common Stock and Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares

Compare the businesses

Genelux Corporation Common Stock

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Open GNLX dashboard ↗

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.

Open KNSA dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗